hVIVO (LON:HVO - Get Free Report) released its quarterly earnings data on Thursday. The company reported GBX 1.69 ($0.02) earnings per share for the quarter, Digital Look Earnings reports. hVIVO had a return on equity of 47.93% and a net margin of 25.96%.
hVIVO Stock Performance
HVO stock traded up GBX 0.15 ($0.00) during midday trading on Tuesday, hitting GBX 16.40 ($0.22). 1,368,712 shares of the stock traded hands, compared to its average volume of 3,222,340. hVIVO has a 1-year low of GBX 12.60 ($0.17) and a 1-year high of GBX 31 ($0.41). The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock's fifty day simple moving average is GBX 16.03 and its 200-day simple moving average is GBX 20.64. The firm has a market cap of £116.04 million, a P/E ratio of 6.76 and a beta of 0.97.
Insiders Place Their Bets
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.22), for a total transaction of £520,581.82 ($686,421.18). Insiders own 14.03% of the company's stock.
Wall Street Analyst Weigh In
Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a report on Thursday, April 10th.
Check Out Our Latest Analysis on HVO
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
